Painful attacks of Raynaud’s phenomenon occur in almost all patients with systemic sclerosis, often referred to as 'scleroderma'.
Although we have a wide range of drug therapies for Raynaud's readily available (and often relatively inexpensive), benefit varies between patients. Many patients also may experience side effects (e.g., headache, nausea, light-headiness), which can range from mild to severe.
Our aim is to understand patient decision-making; that is, how people living with scleroderma balance the benefit and safety of drug treatments used for Raynaud's phenomenon.
We invite you to complete our survey – a “discrete choice experiment” (DCE) – investigating how patients choose treatments for Raynaud's phenomenon.
This survey should take around 10-15 minutes (or less) and is completely anonymous and confidential.
You need be age 18 years or older AND have a confirmed clinical diagnosis of systemic sclerosis/scleroderma with Raynaud's phenomenon to take part in this current study.
After a few questions about your socio-demographic and background characteristics, you will be presented with approximately 40-50 pairs of scenarios related to hypothetical treatment options and asked to choose between them. Please don’t agonise too much, as there are no “correct” answers – we are interested in your personal preferences!
Please take the time to carefully read the study Patient Information Sheet:
PATIENT INFORMATION SHEET
For any issues, please contact: Michael.hughes-6@manchester.ac.uk
Many thanks in advance for your time and collaboration!
Yours Sincerely, Dr Michael Hughes (Manchester, UK) and Prof Dinesh Khanna (Michigan, USA)
Preparing your survey…